The Company is pleased to announce the completion of its recent private placement of 4,258,000 units (the “Units”) at a price of $2.50 per unit for gross proceeds of $10,645,000. Each Unit consists of one common share and one non-transferable share purchase warrant (the “Warrant”). Each Warrant entitles the holder to purchase one common share at a price of $2.50 for a period of one year.
One of the significant placees is the Chow Tai Fook Group, the parent company of the New World Development Company Limited, one of the largest business conglomerates in Hong Kong. New World is a significant player in real estate, infrastructure projects, strategic investments, hotel management, telecommunications, and public transportation. Mr. Cheng Yu-Tung, the Chairman of the Chow Tai Fook Group also serves as Chairman of New World, which is one of the largest shareholders in China.com. Mr. Cheng also serves as a Director of several large Hong Kong companies including Hang Seng Bank Limited.
Dragon Pharmaceuticals, the largest EPO producer in China, is currently a leading biotech company focusing on the research, development, production, and marketing of biodrugs throughout China.
The foregoing includes forward looking statements and readers should not place undue reliance on such forward looking statements, which only reflect the view of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.
Shop Dragon Pharma Steroids
285 total views, 1 today